Concenter BioPharma
Drugs for the Treatment and Prevention of Type 2 Diabetes
Company Overview
Snapshot
Founded in January 2014 by Dror Chevion and Prof. Mordechai (Mottie) Chevion, Concenter BioPharma operates with 1-10 employees. The company has raised $3.18M across 3 funding rounds from 2 investors. In January 2026, Concenter BioPharma secured funding from ExitValley.
Business overview
Concenter BioPharma is a Health Tech & Life Sciences company focused on developing drugs for the treatment and prevention of type 2 diabetes. The company has created a platform of nonsteroidal chemical complexes, derived from clinically approved components, which act as anti-inflammatory, iron-chelating, and antibiotic agents. These new chemical entities are designed to address the causes and symptoms of multiple indications, serving the pharmaceutical and biotechnology sectors in markets including the United States, Asia, and Europe.
Strategic signal
In January 2020, Concenter BioPharma's drug development efforts for type 2 diabetes were highlighted, signaling potential for a novel therapeutic approach to a widespread chronic condition. This indicates the company's progress in clinical-stage product development and its relevance in addressing significant unmet medical needs within the pharmaceutical industry.
Company Intelligence Q&A
- What is Concenter BioPharma's primary focus?
- Concenter BioPharma develops drugs for treating and preventing type 2 diabetes, utilizing a platform of nonsteroidal chemical complexes.
- When was Concenter BioPharma founded?
- Concenter BioPharma was founded in January 2014.
- Who are the founders of Concenter BioPharma?
- Concenter BioPharma was co-founded by Dror Chevion and Prof. Mordechai (Mottie) Chevion.
- What was a key news highlight for Concenter BioPharma in January 2020?
- In January 2020, news highlighted Concenter BioPharma's development of a pill aimed at addressing the root cause of diabetes.